Citadel Advisors
ELAB icon

Citadel Advisors’s Elevai Labs ELAB Stock Holding History

Citadel Advisors’s Portfolio ELAB Stock Details ELAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Buy
+2,070
New +$52.4K ﹤0.01% 13354
2025
Q3 		– Sell
-21
Closed -$38.5K – 13059
2025
Q2 		$38.5K Buy
+21
New +$45.4K ﹤0.01% 11895

Other funds holding ELAB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's ELAB Position: Q2 2026 in Review

Citadel Advisors opened a new position in Elevai Labs (ELAB) in Q2 2026: 2,070 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #13354 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ELAB as recently as Q2 2025.

Citadel Advisors first reported a position in ELAB in Q2 2025 and has held it in 2 quarters since. The position peaked at $38.5K in Q2 2025. 11 funds tracked by Wall St. Rank hold ELAB as of Q2 2026.

  • Citadel Advisors held 2,070 shares of Elevai Labs worth $25K as of Q2 2026.
  • Elevai Labs was a new Citadel Advisors position in Q2 2026.
  • Elevai Labs made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13354 holding.
  • Citadel Advisors first reported a position in Elevai Labs in Q2 2025 and has held it in 2 quarters since.
  • Citadel Advisors's Elevai Labs position peaked at $38.5K in Q2 2025.
  • 11 funds tracked by Wall St. Rank held Elevai Labs as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.